Could these ASX shares be set to benefit from increasing Russian sanctions?

A leading fund manager says there may be further tailwinds for select ASX shares.

| More on:
A man looks at his laptop waiting in anticipation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Growing pressure to up sanctions against Russia could give some ASX shares a second lift
  • Datt Capital picks five of its favourite ASX shares that could benefit from tighter global sanctions
  • These include coal, base metal, and steel companies listed on the ASX

Calls for tighter Russian sanctions following alleged war crimes in Bucha could give some ASX shares a second boost.

Our market has already been outperforming since Russia invaded Ukraine. The conflict is driving up commodity prices and a new round of global sanctions could give commodities another leg up.

This puts resource-rich ASX shares in the driver's seat even as inflation and economic growth risks weigh on the broader market.

ASX coal shares among the sanction winners

If you are wondering which shares on our bourse are best placed to outperform, Datt Capital's managing director Emanuel Datt has picked five to watch in an article on Livewire.

Whitehaven Coal Ltd (ASX: WHC) and New Hope Corporation Limited (ASX: NHC) are on Datt's list.

Whitehaven sells thermal coal to Japanese and Korean customers, while New Hope produces thermal coal from its majority-owned Bengalla mine located in NSW.

ASX shares looking cheap in this climate

"Whitehaven trades at just over 1x expected [earnings before interest, tax, depreciation and amortisation] EBITDA at current thermal coal spot prices and is currently buying back 10% of its shares on market," said Datt.

"New Hope trades at just over 1x expected EBITDA at current thermal coal spot prices and is due to pay an interim fully franked dividend of 30c a share (equating to over 12% yield grossed up).

"The company has one of the highest franking credit balances of any company on the ASX and we expect the board to release this embedded value to shareholders in a timely manner."

Another ASX mining share in the commodities box seat

Another ASX share to watch is South32 Ltd (ASX: S32). The diversified miner is a significant producer of base metals, aluminium, and coking coal.

"S32 is highly capital disciplined and has been buying back its shares on-market since 2017 and this continues today," Datt explained.

"These repurchases have been highly value-accretive to shareholders and the company trades at approximately 2x EBITDA at current spot prices."

Two ASX shares shining bright

The BlueScope Steel Limited (ASX: BSL) share price also looks cheap in this environment. The steel producer is buying back around 10% of its shares on-market and trades at circa 2x EBITDA. That's arguably too low given its strong fundamentals and positive outlook for steel prices and demand, added Datt.

The tailwinds behind the BlueScope share price should also benefit the Vulcan Steel Ltd (ASX: VSL) share price.

Recently listed on the ASX, Vulcan is a steel distribution business operating in the ANZ region.

Is this ASX share set to double in price?

"Vulcan is experiencing excellent tailwinds from these inflationary markets with reported EBITDA per tonne of steel sold doubling in HY22 relative to FY2022," said Datt.

"The business has several attractive qualitative factors which make the present value quite compelling and we value the business around 50% higher than present market prices."

Motley Fool contributor Brendon Lau owns BlueScope Steel Limited and South32 Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Three small children reach up to hold a toy rocket high above their heads in a green field with a blue sky above them.
Growth Shares

These 4 ASX 200 stocks could jump another 70% to 80% in 2026

These stocks are expected to rocket higher.

Read more »

Two excited woman pointing out a bargain opportunity on a laptop.
Share Gainers

3 ASX 200 stocks jumping higher in this week's falling market

Investors shrugged off the broader market retrace and piled into these three ASX 200 stocks this week.

Read more »

A woman with a sad face looks to be receiving bad news on her phone as she holds it in her hands and looks down at it.
Share Fallers

Why EOS, Lotus Resources, REA, and Web Travel shares are dropping today

These shares are ending the week deep in the red. But why?

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Gainers

Why Brambles, HMC Capital, ResMed, and Rio Tinto shares are rising today

These shares are avoiding the selloff and are pushing higher on Friday.

Read more »

A woman looks shocked as she drinks a coffee while reading the paper.
Share Fallers

Why is the Web Travel share price crashing 41% on Friday?

ASX investors are pummelling Web Travel shares today. But why?

Read more »

A man looking at his laptop and thinking.
Materials Shares

Rio Tinto shares charge higher after Glencore merger collapses

The parties couldn't come to an agreement.

Read more »

a group of doctors and medical staff in uniform high five in celebration in a hospital setting
Share Market News

Neuren Pharmaceuticals kicks off Phase 3 trial in rare syndrome

Neuren Pharmaceuticals shares are on watch after dosing began in its key Phase 3 trial for Phelan-McDermid syndrome.

Read more »